MARKET

MBRX

MBRX

Moleculin
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.080
-0.030
-2.70%
After Hours: 1.090 +0.01 +0.93% 19:45 08/07 EDT
OPEN
1.080
PREV CLOSE
1.110
HIGH
1.090
LOW
1.070
VOLUME
1.04M
TURNOVER
--
52 WEEK HIGH
1.970
52 WEEK LOW
0.3230
MARKET CAP
65.24M
P/E (TTM)
-4.7556
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average MBRX stock price target is 3.333 with a high estimate of 5.00 and a low estimate of 2.000.

EPS

MBRX News

More
Coronavirus update: U.S. case tally climbs above 3.8 million; President Trump appears to have changed his view on face masks
marketwatch.com · 07/22 06:39
Dow, S&P close higher as Covid-battered stocks surge, but off session’s best levels as tech sector sinks
marketwatch.com · 07/21 17:24
Moleculin Pops 33% On Anti-Viral Activity For Potential Covid-19 Treatment
SmarterAnalyst · 07/21 14:59
Moleculin Shares Jump on Progress With Virus-Drug Candidate
TheStreet.com · 07/21 14:36
Moleculin's WP1122 shows anti-SARS-CoV-2 effect in new lab tests
Seeking Alpha - Article · 07/21 12:54
Moleculin's WP1122 confirms antiviral potential against coronavirus
Seeking Alpha - Article · 07/21 12:54
Moleculin Biotech says second lab test found antiviral activity for potential COVID-19 treatment
MarketWatch · 07/21 12:46
Moleculin Announces New Independent In Vitro Testing Confirms Antiviral Activity of WP1122 in Coronavirus
PR Newswire · 07/21 12:30

Industry

Pharmaceuticals
+0.19%
Pharmaceuticals & Medical Research
+0.08%

Hot Stocks

Symbol
Price
%Change

About MBRX

Moleculin Biotech, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the treatment of cancers. Its clinical stage drug candidates include Annamycin, WP1066, WP1220, WP1732, WP1122 and WP1234. Annamycin is intended for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. WP1066 is an immune/transcription modulator (p-STAT3 inhibitor) and is intended to target a wide range of tumors, including brain tumors and pancreatic cancer. WP1220 is intended for the topical treatment of cutaneous T-cell lymphoma (CTCL). WP1732 is evaluated for the potential treatment of AML, pancreatic and other cancers. WP1122 and WP1234 are evaluated for the potential to treat brain tumors and pancreatic cancer through its ability to inhibit glycolysis. It is also engaged in development of drug candidates, including additional immune/transcription modulators, as well as metabolism/glycosylation inhibitors.
More

Webull offers kinds of Moleculin Biotech Inc stock information, including NASDAQ:MBRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MBRX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MBRX stock methods without spending real money on the virtual paper trading platform.